Early HPV-Related Cancer Screening with HPV16-E6 Blood Test for HIV and non-HIV Adults
Official title: Early Biomarkers for HPV-Driven Cancers: Modeling Risks and Screening
Funded at International Agency for Res on Cancer · NIH-11270862 · Data updated 2026-11-12
Researchers will study a blood biomarker test to flag several HPV-related cancers early, especially in people living with HIV, to help with timely screening and prevention.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | International Agency for Res on Cancer NIH-funded |
| Lab location | 1 site (Lyon, France) |
| Project start | September 5, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $322,139 |
| NIH project number | 1R01CA307572-01 |
| Project ID | NIH-11270862 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults in the United States, especially individuals living with HIV, who might be at risk for HPV-related cancers and could be eligible for targeted screening in the future.
✕Less likely to help
People without HPV-related cancer risk or those not considering HPV16-E6-based screening may not benefit from this research.
What this research studies
This project focuses on a blood test for antibodies against HPV16-E6 that could indicate a future risk of HPV-related cancers such as oropharyngeal and anal cancers. The team will estimate how likely people with a positive test are to develop these cancers over time, comparing HIV-negative individuals and people living with HIV in the United States. By refining eligibility criteria and screening intervals, the study aims to guide practical, population-level screening strategies. The work combines epidemiological risk modeling with analyses of existing data to inform recommendations for early detection.
Why it matters
Potential benefit: If successful, the findings could lead to improved early detection and more personalized screening schedules for people at higher risk of HPV-related cancers.
How similar studies have gone: Prior studies have shown high specificity and sensitivity for the HPV16-E6 biomarker, supporting potential utility in screening, though gaps remain for risk stratification and screening intervals.
Where this research is happening
-
International Agency for Res on Cancer
Lyon, France Active
Researchers
- Principal investigator: Robbins, Hilary a. — International Agency for Res on Cancer
- Study coordinator: Robbins, Hilary a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.